In addition, ErbB2 has been shown to be an attractive target for ErbB2-positive breast cancer, and several ErbB2-targeting agents, such as trastuzumab, pertuzumab, and lapatinib, have been approved for the treatment of ErbB2-positive breast cancer by the U.S. Food and Drug Administration 31. The gene discussed is ERBB2; the disease is breast carcinoma.